VERTAP

Research Group in addressing vertigo in primary care

1.Improve the approach of vertigo in Primary Care. 2.Improve the diagnosis and treatment of vertigo through online training with face-to-face reinforcement (Project current). 3.Improve the approach of vertigo through an algorithm within the Ecap (Future project).

The group participates in the following projects

PI: Morros Pedrós, Rosa. Mild-moderate respiratory symptoms in patients with long-COVID-19: montelukast clinical trial and biological characterization (ESPERANZA COVID). Funding: Instituto de Salud Carlos III. Duration: 2022 - 2025

PI: Lumillo Gutierrez, Iris. Disseny i avaluació d'un programa d'atenció integral multidisciplinar en la Malaltia Renal Crònica Avançada (MaReCA). Funding: Departament de Salut. Duration: 2022 - 2024

PI: Díaz Herrera, Miguel Ángel. Utilització de termografia dèrmica infraroja rutinària en el diagnòstic precoç de Peu Diabètic d'alt risc (neuropàtics, neuroisquèmics i amb trastorns angiosomals subclínics). Funding: Departament de Salut. Duration: 2022 - 2024

PI: Ballvé Moreno, José Luis. Efectividad de una intervención formativa para mejorar el abordaje de los pacientes con vértigo en atención primaria. Ensayo clínico VERTAP.. Funding: Instituto de Salud Carlos III. Duration: 2020 - 2024

PI: Salvador Gonzalez, Betlem. Ensayo clínico doble-ciego aleatorizado controlado con placebo para evaluar la eficacia en la sintomatología respiratoria leve-moderada de montelukast en pacientes con COVID persistente, PROYECTO E-SPERANZA COVID. Funding: Universitat Autònoma de Barcelona (UAB). Duration: 2021 - 2023

PI: Mera Cordero, Francisco. Mild-moderate respiratory symptoms in patients with long-COVID-19: biological characterization and response to montelukast (E-SPERANZA COVID). Funding: ICS - Institut Català de la Salut. Duration: 2021 - 2023

PI: Salvador Gonzalez, Betlem. Avaluació de l'impacte de l'obertura de l'oci nocturn - Reobrim Sitges. Funding: ICS - Institut Català de la Salut. Duration: 2021 - 2023

PI: - -, IP no primaria. SARS-CoV-2 and other respiratory viruses in childhood: different approaches to define predictive models for their diagnosis and epidemiological evolution. Funding: Fundacio La Marato de TV3. Duration: 2021 - 2023

PI: Peguero Rodríguez, Eva. NystaREC. Funding: Barcelona Mobile Ventures, S.L . Duration: 2022 - 2022

PI: Díaz Herrera, Miguel Ángel. Análisis y descripción de costes derivados del cuidado de heridas crónicas (lesiones por presión, úlceras de etiología venosa, úlceras de etiología arterial y pie diabético) en atención primaria en la zona metropolitana sur de Barcelona. Funding: ICS - Institut Català de la Salut. Duration: 2021 - 2022

The group participates in the following publications

Agustí C, Cunillera O, Almeda J, Mascort J, Carrillo R, Olmos C, Montoliu A, Alberny M, Molina I, Cayuelas L, Casabona J. Efficacy of an electronic reminder for HIV screening in primary healthcare based on indicator conditions in Catalonia (Spain). HIV Med. 2022 Mar; doi:10.1111/hiv.13270. Epub 2022 Mar 13. PMID:35285143. IF: 3,180.

Blanquer-Genovart M, Manera-Bassols M, Salvador-Castell G, Cunillera-Puértolas O, Castell-Abat C, Cabezas-Peña C. School Menu Review Programme (PReME): evaluation of compliance with dietary recommendations during the period 2006-2020 in Catalonia. BMC Public Health. 2022 Nov; 22(1):2173. doi:10.1186/s12889-022-14571-1. Epub 2022 Nov 25. PMID:36434578. IF: .

Dopico E, Rodriguez-Frias F, Ubillos I, Rando-Segura A, Garcia-Cehic D, Gregori J, Rando-Matos Y, Solsona L, Niubó J, Esteban JI, Costa J, Martínez MJ, Quer J. Prevalence of Hepatitis C Virus Infection, Genotypes and Subtypes in Migrants from Pakistan in Barcelona, Spain. Infect Drug Resist. 2022 ; 15:4637-4644. doi:10.2147/IDR.S367715. Epub 2022 Aug 18. pmc:PMC9394658. PMID:36003985. IF: .

López-Cobo I, Rodriguez-Latre L, Cunillera O, Ruiz I, Copetti S, Albareda M, Vila L. Trends in glycemic control, cardiovascular risk factors and chronic complications of type 2 diabetes, 2012-2016, in a healthcare area of Barcelona. Diabetes Res Clin Pract. 2022 Aug; 190:110014. doi:10.1016/j.diabres.2022.110014. Epub 2022 Jul 21. PMID:35870572. IF: 5,602.

Mera-Cordero F, Bonet-Monne S, Almeda-Ortega J, García-Sangenís A, Cunillera-Puèrtolas O, Contreras-Martos S, Alvarez-Muñoz G, Monfà R, Balanzó-Joué M, Morros R, Salvador-Gonzalez B. Correction to: Double-blind placebo-controlled randomized clinical trial to assess the efficacy of montelukast in mild to moderate respiratory symptoms of patients with long COVID: E-SPERANZA COVID Project study protocol. Trials. 2022 Feb; 23(1):130. doi:10.1186/s13063-022-06073-7. Epub 2022 Feb 09. pmc:PMC8827194. PMID:35139906. IF: .

Mera-Cordero F, Bonet-Monne S, Almeda-Ortega J, García-Sangenís A, Cunillera-Puèrtolas O, Contreras-Martos S, Alvarez-Muñoz G, Monfà R, Balanzo-Joué M, Morros R, Salvador-Gonzalez B. Double-blind placebo-controlled randomized clinical trial to assess the efficacy of montelukast in mild to moderate respiratory symptoms of patients with long COVID: E-SPERANZA COVID Project study protocol. Trials. 2022 Jan; 23(1):19. doi:10.1186/s13063-021-05951-w. Epub 2022 Jan 06. pmc:PMC8733792. PMID:34991703. IF: .

Patiño JEP, Moreno JLB, Matos YR, Ortega JA, Puértolas OC, Muñoz RC, Balboa IV, Compta XG, Agudelo OLA, Muñoz SC, Rodríguez VM, Cortes AN, Rodríguez EP. Effectiveness of a training intervention to improve the management of vertigo in primary care: a multicentre cluster-randomised trial, VERTAP. Trials. 2022 Jul; 23(1):608. doi:10.1186/s13063-022-06548-7. Epub 2022 Jul 29. pmc:PMC9335455. PMID:35906606. IF: .

Pérez JE, Ballvé JL, Rando Y, Almeda J, Cunillera O, Carrillo R, Villar I, Gonzalez FX, Arias OL, Calero S, Monforte V, Navarro A, Peguero E. Effectiveness of a training intervention to improve the management of vertigo in primary care: a multicentre cluster-randomized trial. Res Sq. 2022; Prepint. IF: .

Indicators

Indicator

2022

Researchers with PhD

4

Total number of projects in which group members have participated

13

Total number of projects in which the PI of the project has belonged to the group

2

Total Funding

776.221,52€

Scientific publications in indexed journals

2

Total Impact factor

8,78

Nº of articles in Q1 journals

1

Q1 IF

5,602

Nº of articles in Q2 journals

0

Q2 IF

 
Anar a l'inici